Adderall stimulant medication

Adderall is a prescription stimulant medication primarily used to treat Attention Deficit Hyperactivity Disorder (ADHD) and narcolepsy. Originally formulated as a weight-loss drug called Obetrol in the 1960s, it was rebranded and approved as Adderall in the mid-1990s by Richwood Pharmaceuticals (which later merged with Shire). The drug is composed of a mixture of four amphetamine salts: amphetamine aspartate, amphetamine sulfate, dextroamphetamine saccharate, and dextroamphetamine sulfate.

Today, the Adderall brand is synonymous with its original developer Shire, which was acquired by the Japanese pharmaceutical giant Takeda Pharmaceutical Company in 2019. While Takeda owns the brand lineage, the rights to the brand-name Adderall IR (Immediate Release) and Adderall XR (Extended Release) in the United States have transitioned through various agreements. Currently, Teva Pharmaceutical Industries, an Israeli-based global leader in generics, is the most prominent manufacturer of both the brand-name version and generic equivalents. Manufacturing occurs across a global network of facilities, primarily in the United States and Israel, to meet the high demand for the medication.

As of 2026, the market remains complex due to the widespread availability of generics from numerous companies like Sandoz, Alvogen, and Elite Pharmaceuticals. Despite the brand's Japanese ownership via Takeda, its operational heart for the U.S. market continues to be heavily managed by Teva, reflecting the intricate consolidation typical of the modern pharmaceutical industry.